Cervical cancer cell–derived angiopoietins promote tumor progression

Metastatic or recurrent cervical cancer has limited treatment options and a high rate of mortality. Although anti-vascular endothelial growth factor drugs have shown great promise as a therapeutic target for treatment of advanced cervical cancer, drug resistance and class-specific side effects negate long-term benefits. The identification of alternative anti-angiogenic factors will be critical for future drug development for advanced or recurrent cervical cancer. In this study, we found that angiopoietins and Tie receptors were highly expressed in cervical cancer cells. Tie-2 expression in tumor cells predicted poorer prognosis. Wound closure assay and Transwell assay showed that upregulated or downregulated Ang-1 and Ang-2 expression promoted or reduced cervical cancer cell lines migration and invasion, respectively. In subcutaneous xenograft models of cervical cancer, downregulation of Ang-1 and Ang-2 attenuated tumor growth. The expression of vimentin and endomucin and microvessel density were all significantly decreased in the siAng-1 group and siAng-2 group relative to the infection control group. Our data support that dual inhibition of Ang-1 and Ang-2 may be an alternative target for anti-angiogenic adjuvant therapy in advanced or recurrent cervical squamous cell cancer.

[1]  H. Watari,et al.  Chemotherapy and molecular targeting therapy for recurrent cervical cancer , 2016, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[2]  Jing Cai,et al.  Retrospective comparison of laparoscopic versus open radical hysterectomy after neoadjuvant chemotherapy for locally advanced cervical cancer , 2016, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[3]  D. Cescon,et al.  A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041) , 2015, Investigational New Drugs.

[4]  R. Kerbel.  A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment , 2015, Cancer journal.

[5]  M. Gasparri,et al.  Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386). , 2015, Critical reviews in oncology/hematology.

[6]  B. Monk,et al.  Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). , 2015, The Lancet. Oncology.

[7]  K. Alitalo,et al.  Endothelial destabilization by angiopoietin-2 via integrin β1 activation , 2015, Nature Communications.

[8]  Hyung-chan Kim,et al.  Gln-362 of Angiopoietin-2 Mediates Migration of Tumor and Endothelial Cells through Association with α5β1 Integrin , 2014, The Journal of Biological Chemistry.

[9]  Jing Cai,et al.  The Use of Laser Microdissection in the Identification of Suitable Reference Genes for Normalization of Quantitative Real-Time PCR in Human FFPE Epithelial Ovarian Tissue Samples , 2014, PloS one.

[10]  P. Saharinen,et al.  Angiopoietin signaling in the vasculature. , 2013, Experimental cell research.

[11]  H. Augustin,et al.  Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. , 2013, Cancer research.

[12]  P. Carmeliet,et al.  SnapShot: Tumor Angiogenesis , 2012, Cell.

[13]  M. Felcht,et al.  Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. , 2012, The Journal of clinical investigation.

[14]  X. Yao,et al.  Angiopoietin-2, an Angiogenic Regulator, Promotes Initial Growth and Survival of Breast Cancer Metastases to the Lung through the Integrin-linked Kinase (ILK)-AKT-B Cell Lymphoma 2 (Bcl-2) Pathway* , 2011, The Journal of Biological Chemistry.

[15]  Robert S. Kerbel,et al.  Antiangiogenic therapy: impact on invasion, disease progression, and metastasis , 2011, Nature Reviews Clinical Oncology.

[16]  L. Nguyen,et al.  Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody , 2010, Molecular Cancer Therapeutics.

[17]  Peter Hauff,et al.  Angiopoietin-2 Promotes Disease Progression of Neuroendocrine Tumors , 2010, Clinical Cancer Research.

[18]  Jing Cai,et al.  PlGF expression in pre‐invasive and invasive lesions of uterine cervix is associated with angiogenesis and lymphangiogenesis , 2009, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[19]  Gavin Thurston,et al.  Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system , 2009, Nature Reviews Molecular Cell Biology.

[20]  D. Schadendorf,et al.  Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma , 2009, Clinical Cancer Research.

[21]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[22]  W. Shim,et al.  Angiopoietin: A TIE(d) Balance in Tumor Angiogenesis , 2007, Molecular Cancer Research.

[23]  M. J. Jarzynka,et al.  Angiopoietin-2 Stimulates Breast Cancer Metastasis through the α5β1 Integrin-Mediated Pathway , 2007 .

[24]  T. Nakayama,et al.  Expression of Tie‐1 and 2 receptors, and angiopoietin‐1, 2 and 4 in gastric carcinoma; immunohistochemical analyses and correlation with clinicopathological factors , 2004, Histopathology.

[25]  M. Teh,et al.  Angiopoietin 1 promotes tumor angiogenesis and tumor vessel plasticity of human cervical cancer in mice. , 2002, Experimental cell research.

[26]  M. Teh,et al.  Inhibition of angiopoietin‐1 expression in tumor cells by an antisense RNA approach inhibited xenograft tumor growth in immunodeficient mice , 2001, International journal of cancer.

[27]  G. Christofori,et al.  Angiopoietins in angiogenesis. , 2013, Cancer letters.

[28]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[29]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[30]  H. van Cruijsen,et al.  Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions. , 2009, Frontiers in bioscience.

[31]  M. J. Jarzynka,et al.  Angiopoietin-2 stimulates breast cancer metastasis through the alpha(5)beta(1) integrin-mediated pathway. , 2007, Cancer research.